Several ccRCC cell lines were sensitive to the BIRC5-targeted drug, Sepantronium bromide, thereby suggesting that BIRC5 is a potential therapeutic target for ccRCC patients. Here, BIRC5 is linked to nonpapillary renal cell carcinoma.